Replies to post #158924 on Biotech Values

[north40000]

Are you sure all sales were included in IMS data? I am not.
Let us see what data is available on a monthly total.

AMRN has a similar problem re IMS not including scrips from some significant providers.

[JJM760]

Funny, Padzur called Ponatinib exquisite, yet AF's bio investor buddy called it a dirty drug.

Adam's article is bush league at best. How about talking to some of the Kol's and ask them what they think of the drug prior to writing that garbage.